Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M15,036Revenue $M4,464Net Margin (%)7.5Z-Score4.4
Enterprise Value $M15,989EPS $2.0Operating Margin %10.5F-Score7
P/E(ttm))45.1Cash Flow Per Share $4.7Pre-tax Margin (%)8.7Higher ROA y-yY
Price/Book4.510-y EBITDA Growth Rate %-5.1Quick Ratio1.4Cash flow > EarningsY
Price/Sales3.45-y EBITDA Growth Rate %-10.5Current Ratio2.3Lower Leverage y-yY
Price/Cash Flow6.8y-y EBITDA Growth Rate %221ROA % (ttm)5.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)10.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M171ROI % (ttm)-1.9Gross Margin Increase y-yY

Gurus Latest Trades with HSP

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HSPJoel Greenblatt 2014-12-31 Sold Out -0.16%$48.12 - $62.84
($56.62)
$ 87.8836%Sold Out0
HSPMario Gabelli 2014-12-31 Add0.03%$48.12 - $62.84
($56.51)
$ 87.8836%Add 38.25%352,370
HSPJohn Rogers 2014-09-30 Reduce-0.45%$49.59 - $56.21
($53.12)
$ 87.8840%Reduce -22.28%2,433,369
HSPJoel Greenblatt 2014-09-30 Buy 0.16%$49.59 - $56.21
($53.12)
$ 87.8840%New holding313,242
HSPMario Gabelli 2014-09-30 Add0.01%$49.59 - $56.21
($53.12)
$ 87.8840%Add 24.71%254,870
HSPJohn Rogers 2014-06-30 Reduce-0.53%$42.14 - $52.41
($47.4)
$ 87.8846%Reduce -24.15%3,130,809
HSPMario Gabelli 2014-06-30 Add0.01%$42.14 - $52.41
($47.4)
$ 87.8846%Add 32.91%204,370
HSPRichard Snow 2014-03-31 Sold Out -1.3%$40.89 - $45
($42.84)
$ 87.8851%Sold Out0
HSPBrian Rogers 2014-03-31 Sold Out -0.37%$40.89 - $45
($42.84)
$ 87.8851%Sold Out0
HSPJohn Rogers 2014-03-31 Reduce-0.28%$40.89 - $45
($42.84)
$ 87.8851%Reduce -11.62%4,127,850
HSPVanguard Health Care Fund 2014-03-31 Add0.18%$40.89 - $45
($42.83)
$ 87.8851%Add 22.69%8,375,170
HSPMario Gabelli 2014-03-31 Add0.01%$40.89 - $45
($42.84)
$ 87.8851%Add 30.68%153,770
HSPJohn Rogers 2013-12-31 Add0.12%$38.53 - $42.19
($40.25)
$ 87.8854%Add 5.28%4,670,630
HSPRichard Snow 2013-09-30 Reduce-0.85%$38.45 - $42.03
($39.88)
$ 87.8855%Reduce -36.89%811,590
HSPRichard Pzena 2013-09-30 Sold Out -0.27%$38.45 - $42.03
($39.88)
$ 87.8855%Sold Out0
HSPJohn Rogers 2013-09-30 Reduce-0.23%$38.45 - $42.03
($39.88)
$ 87.8855%Reduce -7.79%4,436,305
HSPJohn Rogers 2013-06-30 Add0.34%$30.57 - $38.31
($33.81)
$ 87.8862%Add 12.97%4,811,105
HSPRichard Snow 2013-06-30 Reduce-0.27%$30.57 - $38.31
($33.81)
$ 87.8862%Reduce -11.68%1,286,067
HSPBrian Rogers 2013-06-30 Add0.24%$30.57 - $38.31
($33.81)
$ 87.8862%Add 135.30%2,750,000
HSPMichael Price 2013-03-31 Add0.65%$28.96 - $35.99
($32.42)
$ 87.8863%Add 61.62%400,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HSP is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


HSP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stober Matthew RSVP, Operations 2015-03-02Sell21,833$87.490.41view
Stober Matthew RSVP, Operations 2015-02-27Sell25,338$87.470.43view
Werner Thomas ESVP, Finance & CFO 2015-02-17Sell1,566$87.350.57view
Werner Thomas ESVP, Finance & CFO 2015-01-15Sell10,000$61.5642.71view
Stober Matthew RSVP, Operations 2015-01-12Sell2,000$61.842.15view
Werner Thomas ESVP, Finance & CFO 2014-12-15Sell10,000$60.8644.35view
Hoffman Richard JCVP, Controller & CAO 2014-12-02Sell21,850$60.3245.64view
SOKOLOV JACQUE JDirector 2014-11-28Sell7,547$60.3245.64view
Yoskowitz Marc JSVP, Strategy & Corporate Dev 2014-11-25Sell11,523$59.9346.59view
Meyers Kenneth FSVP, Chief Human Resources Ofr 2014-11-24Sell46,250$59.6647.25view

Press Releases about HSP :

    Quarterly/Annual Reports about HSP:

    News about HSP:

    Articles On GuruFocus.com
    Hospira’s Q4 Earnings Were Bright, Though Acquisition Is In The Cards Feb 19 2015 
    Analysts Weigh in on Pfizer Following Acquisition Announcement of Hospira Feb 06 2015 
    Feeling Good With This Med Company Jan 20 2015 
    Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
    Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
    Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
    Brian Rogers' T. Rowe Price Equity Income Fund Semi-Annual Report 2013 Dec 02 2013 
    Ariel Capital's John Rogers Trims Sotheby’s, DeVry, Hospira, IPG, Others Nov 18 2013 
    Five Companies Cut - Pzena Investment Management Update Nov 12 2013 
    John Rogers Comments on Hospira Inc. Jul 25 2013 


    More From Other Websites
    FactSet: U.S. M&A Activity Dips in February as Private Equity Surges Mar 26 2015
    Superconductor Technologies, Inc. (SCON), Pfizer Inc. (PFE), ACADIA Pharmaceuticals Inc. (ACAD):... Mar 25 2015
    Johnson & Johnson May See EPS Drag Through 2018 Mar 24 2015
    Biogen downgrade, Pfizer rises Mar 23 2015
    ​Judge rejects Amgen bid to stop biosimilar drug Mar 20 2015
    The Pharmacyclics–AbbVie Merger – Shareholders Could Benefit Mar 20 2015
    AcelRx Starts Pivotal Study on Acute Pain Management Drug - Analyst Blog Mar 17 2015
    How Much Upside Is There in the Macerich–Simon Property Deal? Mar 16 2015
    Background on Simon Property Group Mar 16 2015
    Rationale for the Macerich–Simon Property Transaction Mar 16 2015
    The Macerich–Simon Property Deal: Hostile or friendly? Mar 16 2015
    The Freescale–NXP Merger: Freescale at a glance Mar 16 2015
    Simon Property Sends a Bear Hug Letter to Macerich Mar 11 2015
    The punch line: Is the Freescale–NXP merger a set up? Mar 10 2015
    The Zacks Analyst Blog Highlights: Novartis, Amgen, Hospira, Pfizer and Actavis - Press Releases Mar 10 2015
    Is the Freescale–NXP merger worth the risk? Mar 09 2015
    Medicines Company Angiomax Patent Appeal Hearing Debrief Mar 09 2015
    The Freescale–NXP merger regulatory path to approval Mar 06 2015
    Rationale for the Freescale–NXP merger Mar 06 2015
    Hospira Statement on FDA Approval of the First Biosimilar in the United States Mar 06 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK